The mission of the Pharmacology Core Facility (PCF) is to foster clinical pharmacology and biomarker research regarding cancer therapeutics. The Facility offers comprehensive lab services to support cancer investigators conducting clinical and preclinical drug development studies. The PCF is now comprised of an Analytical Unit and a Biofluids Unit. The labs occupy -3,465 sq ft of space within the Section of Hematology/Oncology, and also utilizes the IV therapy unit (2,662 sq ft) located directly across from the Hematology/Oncology clinic in the Duchossois Center for Advanced Medicine (DCAM). The Core currently works with 169 cancer clinical studies representing 5 UCCCC Programs, and a few tissue procurement studies. Services provided by the PCF include: ? development and implementation of analytical assays for measurement of drugs and metabolites in biological fluids ? pharmacokinetic design and writing assistance for clinical protocols; ? pharmacokinetic/pharmacodynamic modeling; ? research phlebotomy and intravenous cannulation; ? sample processing; ? urine collection; ? specimen storage, tracking and archiving;and ? electrocardiograms.
The research supported by the PCF aims at improving the quality of life and outcome of cancer patients. We help clinical investigators individualize chemotherapy to optimize treatment effectiveness and minimize toxicity. We also facilitate discovery and measurement of biomarkers correlating with pharmacological response to a drug or disease progression.
|Feng, Christine H; Gerry, Emily; Chmura, Steven J et al. (2015) An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 91:58-64|
|Ming, Mei; Zhao, Baozhong; Shea, Christopher R et al. (2015) Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 135:936-45.e4|
|Ming, Mei; Zhao, Baozhong; Qiang, Lei et al. (2015) Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol 91:242-7|
|Shah, Palak; He, Yu-Ying (2015) Molecular regulation of UV-induced DNA repair. Photochem Photobiol 91:254-64|
|Ming, Mei; Han, Weinong; Zhao, Baozhong et al. (2014) SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res 74:5925-33|
|Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32|
|Rudra, Sonali; Al-Hallaq, Hania A; Feng, Christine et al. (2014) Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys 15:4547|
|Weng, Liming; Ziliak, Dana; Lacroix, Bonnie et al. (2014) Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One 9:e93420|
|Stumpf, Melanie; Zhou, Xuyu; Chikuma, Shunsuke et al. (2014) Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44:1737-46|
|Geeleher, Paul; Cox, Nancy J; Huang, R Stephanie (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 15:R47|
Showing the most recent 10 out of 354 publications